Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9931305 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(2 years ago) | |
US9855221 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
US10888499 | SUMITOMO PHARMA AM | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
Feb, 2022
(2 years ago) | |
US11077068 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
US8663687 | SUMITOMO PHARMA AM | Film compositions for delivery of actives |
Feb, 2023
(1 year, 2 months ago) | |
US8765167 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(2 months ago) | |
US8603514 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(20 days ago) | |
US10821074 | SUMITOMO PHARMA AM | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
US9669019 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US9283219 | SUMITOMO PHARMA AM | Sublingual films |
Jun, 2030
(6 years from now) | |
US9326981 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US9044475 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US10420763 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US9669021 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US8846074 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
US8414922 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
US11419769 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
US10959943 | SUMITOMO PHARMA AM | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(11 years from now) | |
US10449146 | SUMITOMO PHARMA AM | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(11 years from now) |
Kynmobi is owned by Sumitomo Pharma Am.
Kynmobi contains Apomorphine Hydrochloride.
Kynmobi has a total of 19 drug patents out of which 7 drug patents have expired.
Expired drug patents of Kynmobi are:
Kynmobi was authorised for market use on 21 May, 2020.
Kynmobi is available in film;sublingual dosage forms.
Kynmobi can be used as treatment of 'off' episodes in patients with parkinson's disease.
The generics of Kynmobi are possible to be released after 19 April, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL